Published in Oncogene on November 08, 2010
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J Clin Invest (2014) 1.13
Akt signaling is required for glioblastoma maintenance in vivo. Am J Cancer Res (2011) 0.94
Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J (2011) 0.93
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res (2012) 0.89
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis (2012) 0.84
p53 is positively regulated by miR-542-3p. Cancer Res (2014) 0.84
Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. J Thyroid Res (2011) 0.84
Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer (2013) 0.82
A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model Mech (2014) 0.80
Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80
The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer (2015) 0.79
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
Gα13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma. Int J Cancer (2015) 0.76
Apoptosis in glioma-bearing rats after neural stem cell transplantation. Neural Regen Res (2013) 0.75
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene (2017) 0.75
HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss. Oncogene (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell (1995) 7.34
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One (2009) 5.08
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology (1998) 2.96
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 2.31
Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta (2006) 2.28
Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene (1996) 2.13
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci U S A (1999) 1.81
The INK4 family of cell cycle inhibitors in cancer. Oncogene (1999) 1.70
The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci (1998) 1.59
Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry (1996) 1.49
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
Essential role for Ras signaling in glioblastoma maintenance. Cancer Res (2005) 1.22
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J (1996) 6.66
Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell (1998) 3.59
Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol (1995) 2.19
PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature (1997) 2.08
Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc Natl Acad Sci U S A (1999) 1.81
Irregular presence of abnormal prion protein in appendix in variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2002) 1.72
Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell (1994) 1.64
Extensive spherical amyloid deposition presenting as a pituitary tumor. J Endocrinol Invest (2003) 1.40
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene (2012) 1.34
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain (2008) 1.30
Neuroimaging of cerebellar liponeurocytoma. Case report. J Neurosurg (2001) 1.19
Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet (1996) 1.18
Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene (2007) 1.09
Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol (2012) 1.08
The role of PrP in pathogenesis of experimental scrapie. Cold Spring Harb Symp Quant Biol (1996) 1.01
Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases. Neuropathol Appl Neurobiol (2008) 0.99
Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). Neuropathol Appl Neurobiol (2009) 0.98
Prion infectivity in variant Creutzfeldt-Jakob disease rectum. Gut (2006) 0.96
Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver (2000) 0.95
High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease. Gut (2005) 0.94
Efficient lipid-mediated transfection of DNA into primary rat hepatocytes. In Vitro Cell Dev Biol Anim (1995) 0.94
Microsurgical management of lateral lumbar disc herniations: combined lateral and interlaminar approach. Acta Neurochir (Wien) (1996) 0.94
Variable phenotypes are associated with PMP22 missense mutations. Neuromuscul Disord (2010) 0.93
Activation of HIV transcription by human foamy virus in transgenic mice. Lab Invest (1995) 0.91
Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11p and 17p in medulloblastomas. Neuropathol Appl Neurobiol (1994) 0.91
Transgenic and knockout mice in research on prion diseases. Brain Pathol (1998) 0.90
Anatomy of the auditory thalamocortical system of the guinea pig. J Comp Neurol (1989) 0.89
The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. Int J Exp Pathol (1996) 0.89
Brain cell type specificity and gliosis-induced activation of the human cytomegalovirus immediate-early promoter in transgenic mice. J Neurosci (1996) 0.89
Symptomatic cerebellar metastasis and late local recurrence of a cauda equina paraganglioma. Case report. J Neurosurg (1995) 0.88
Normal neurogenesis and scrapie pathogenesis in neural grafts lacking the prion protein homologue Doppel. EMBO Rep (2001) 0.88
The heavy metal-responsive transcription factor-1 (MTF-1) is not required for neural differentiation. Biol Chem (1999) 0.84
Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene (2001) 0.84
Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia (1995) 0.83
Kell and XK immunohistochemistry in McLeod myopathy. Muscle Nerve (2001) 0.83
Differentiation and histological analysis of embryonic stem cell-derived neural transplants in mice. Brain Pathol (2000) 0.83
The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. Rev Sci Tech (1998) 0.82
Analysis of the determinants of neurotropism and neurotoxicity of HFV in transgenic mice. Virology (1996) 0.82
A novel mitochondrial tRNA(Phe) mutation inhibiting anticodon stem formation associated with a muscle disease. Biochem Biophys Res Commun (1998) 0.82
Secondary manifestation of medulloblastoma: metastases and local recurrences in 66 patients. Acta Neurochir (Wien) (1995) 0.82
Transgenic and knockout mice in the study of neurodegenerative diseases. J Mol Med (Berl) (1996) 0.81
Functional organization of the auditory thalamus in the guinea pig. Exp Brain Res (1991) 0.81
Transgenic and knock-out mice: models of neurological disease. Brain Pathol (1994) 0.81
Prions: pathogenesis and reverse genetics. Ann N Y Acad Sci (2000) 0.80
Second primary glioblastoma. J Neuropathol Exp Neurol (2001) 0.80
Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathol Appl Neurobiol (1996) 0.80
147th ENMC international workshop: guideline on processing and evaluation of sural nerve biopsies, 15-17 December 2006, Naarden, The Netherlands. Neuromuscul Disord (2007) 0.78
Neuroectodermal grafting: a new tool for the study of neurodegenerative diseases. Histol Histopathol (1996) 0.78
Lhermitte-Duclos disease in 3 children: a clinical long-term observation. Neuropediatrics (2003) 0.78
Spongiform encephalopathies: insights from transgenic models. Adv Virus Res (2001) 0.77
Neurotoxicity and neuroinvasiveness of prions. J Neurovirol (1997) 0.77
Comparative in vivo and pathological analysis of the blood-brain barrier in mouse telencephalic transplants. Neuropathol Appl Neurobiol (1996) 0.76
Prions: from neurografts to neuroinvasion. Arch Virol Suppl (2000) 0.76
The AMOG/beta 2 subunit of Na,K-ATPase is not necessary for long-term survival of telencephalic grafts. Glia (1995) 0.76
Human phenol sulfotransferases hP-PST and hM-PST activate propane 2-nitronate to a genotoxicant. Carcinogenesis (2000) 0.76
Use of brain grafts to study the pathogenesis of prion diseases. Essays Biochem (1998) 0.76
Synaptophysin in choroid plexus epithelial cells: no useful aid in differential diagnosis. J Neuropathol Exp Neurol (1999) 0.75
Shrinking prions: new folds to old questions. Nat Med (1999) 0.75
Molecular analysis of development and neoplasia: homologous recombination and knock-out approaches, Schloss Reisenburg, Germany, March 22nd, 1994. Brain Pathol (1994) 0.75
Transgenic mice as research tools in neurocarcinogenesis. J Neurovirol (1998) 0.75
Prions: from neurografts to neuroinvasion. Methods Mol Med (2001) 0.75
Malignant rhabdoid tumor of the brain: quantitative 1H MR-spectroscopy and cytogenetics. Neuropediatrics (2000) 0.75
Meningeal hemangiopericytoma in childhood. Eur Radiol (2000) 0.75
Primary Candida albicans empyema associated with epidural hematomas in craniocervical junction. Clin Neuropathol (1997) 0.75
Tracking prions: the neurografting approach. Cell Mol Life Sci (1997) 0.75
Hyperventilation due to mitochondrial myopathy. J R Soc Med (2000) 0.75
Mice homozygous for a modified beta-amyloid precursor protein (beta APP) gene show impaired behavior and high incidence of agenesis of the corpus callosum. Ann N Y Acad Sci (1996) 0.75
[The new research frontier on prion disease]. Pathologica (1998) 0.75
[Molecular pathogenesis of spongiform encephalopathy]. Pathologica (1997) 0.75
[Morphology and development of neural transplants of AMOG-deficient mice]. Verh Dtsch Ges Pathol (1994) 0.75
[Significance of prion protein in transmission of prions and in pathogenesis of spongiform encephalopathies]. Wien Med Wochenschr (1998) 0.75
The genetics of prions--a contradiction in terms? Lancet (1999) 0.75
[Vasculitis and mononeuritis multiplex]. Praxis (Bern 1994) (2000) 0.75
Severe hypothermia in a patient with cerebral relapse of Whipple's disease. Infection (2004) 0.75